Michael Scholle

Co-Founder

Michael Scholle serves as Operations Director and Site Head, Discovery for Charles River Laboratories, and was Chief Operating Officer and co-founder of SAMDI Tech, Inc. (now a CRL company). 

He brings more than 25 years of experience in building biotech companies, commercializing technology platforms, high throughput drug discovery, MALDI TOF mass spectrometry, biochemistry, molecular biology, and antibody discovery.

Prior to CRL/SAMDI Tech, Scholle held various scientific positions at Integrated Genomics Inc, Argonne National Laboratory, and Amunix Inc. At Amunix (acquired by Sanofi in 2022), he was a founding scientist and played a key role in the development of XTEN, a half-life enhancing technology.  The XTEN technology was licensed by Versartis and exited with an IPO in 2013. Scholle has also served on the Board of Directors at Amunix and now Tango Biosciences.  He has authored over 30 peer-reviewed articles published in scientific and business journals.

Scholle earned a master’s degree in biology from Northern Illinois University and an MBA from Roosevelt University-Chicago.